vTv Therapeutics Inc.

NASDAQ:VTVT

Biotechnology

Healthcare
$16.23 +1.47%

+$0.50 today

Market cap
$64.17M
Beta
0.27
P/E (TTM)
128.7
EPS (TTM)
$0.27
52W Low $14.00High $44.00

Volume 0.02M

Average 0.05M

VTVT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

vTv Therapeutics Inc.NASDAQ: VTVT

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns positive

Q1 FY2026 net income was $24.13M, compared with -$6.22M a year earlier. Trailing-twelve-month net income was $918K. Over 3 fiscal years it compounded at +17.5% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$14.44M (-53.5%) for the fiscal year ending Dec 2026, a slowdown from the +36.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.13M+438.1% QoQ
Last fiscal yearDec 2025
-$31.08M+36.9% YoY
LTMMar 2026
$918K+104.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+488.2%+63.3%-424.9 pp
1 year+36.9%-53.5%-90.4 pp
3-year CAGR+17.5%+6.4%-11.1 pp
5-year CAGR-4.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(31.08M) USD
Year-over-year change
-36.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How VTVT compares with its peers on the latest reported figures

  • VTVT's LTM Mar 2026 net income of $918K is the smallest of the 9 companies compared; the peer median is $35.9M.
  • Its year-over-year change of +104.2% is the 4th highest of 9, against a peer median of +1.6%.
  • Net income amounts to 2.5% of revenue for VTVT, versus a peer median of 617.5%.
VTVT Competitors Peer median
Net Income for VTVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$28.76B +254398.4%+1562.8%—
INKTMiNK Therapeutics, Inc.LTM Mar 2026$12.49B +128201.2%-23.6%—
FBIOFortress Biotech, Inc.LTM Mar 2026$102.15M +215.2%-46.4%154.4%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$60.96M -388.6%-1.9%18297.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$37.19M -32.9%-5.5%—
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$34.61M -52.7%+4.2%164.8%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$24.54M +1.8%-10.4%1070.2%
GANXGain Therapeutics, Inc.LTM Mar 2026$21.24M +1.5%+4.7%—
VTVTvTv Therapeutics Inc.LTM Mar 2026$918K +104.2%+17.5%2.5%
Peer median (excluding VTVT) $35.9M+1.6%-3.7%617.5%

Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.73M)(19.16M)(20.25M)(22.71M)(31.08M)
Depreciation & Amortization89K92K90K89K16K
Deferred Income Tax00000
Stock-Based Compensation2.36M01.58M2.76M3.78M
Change in Working Capital35K5.39M4.39M(5.44M)1.89M
Accounts Receivables101K(116K)71K40K0
Inventory(889K)0000
Accounts Payables1.83M(856K)2.93M01.53M
Other Working Capital(1.01M)6.36M1.39M(5.48M)362K
Other Non-Cash Items(4.06M)(1.56M)(4.89M)(10K)142K
Operating Cash Flow(19.31M)(15.25M)(19.08M)(25.31M)(25.26M)
Capital Expenditures0(21K)000
Acquisitions (Net)004.4M00
Purchases of Investments00000
Sales of Investments004.4M00
Other Investing Activities00(4.4M)00
Investing Cash Flow0(21K)4.4M00
Debt Repayment172K(808K)(33K)(191K)(392K)
Common Stock Issued26.76M14.79M12.03M52.8M77.48M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities47K000341K
Financing Cash Flow26.98M13.98M12M52.61M77.44M
Effect of Forex Changes00000
Net Change in Cash7.67M(1.29M)(2.68M)27.3M52.19M
Free Cash Flow(19.31M)(15.27M)(19.08M)(25.31M)(25.26M)

vTv Therapeutics Inc.

NASDAQ:VTVT

Intrinsic Alpha fair value

Locked

Current Price

$16.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.